Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Nielsen
San Diego, California, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
Nielsen BioSciences currently markets FDA-approved biologics for delayed-type hypersensitivity testing (CANDIN for Candida albicans, SPHERUSOL for Valley Fever). Their leading clinical program is a Phase 3 trial of CANDIN for the treatment of common warts (Verruca vulgaris), an HPV-driven condition, in collaboration with Maruho in the U.S. and Japan. CANDIN is not yet approved for wart treatment. Multiple prior clinical studies have been conducted; key results from Phase 2 were positive, supporting progression to Phase 3[1][3][4][7][9].
- Therapeutic areas
- ImmunologyInfectious DiseasesDermatology
- Modalities
- Allergen extractBiologic
- Industry
- Biotech
02
Partnerships
Maruho Co. Ltd.Vial (Clinical CRO)
Beyond the preview
Go deeper on Nielsen.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nielsen.